» Articles » PMID: 31373843

The Development of Inovirus-associated Vector Vaccines Using Phage-display Technologies

Overview
Date 2019 Aug 3
PMID 31373843
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

: Inovirus-associated vectors (IAVs) are derived from bacterial filamentous viruses (phages). As vaccine carriers, they have elicited both cellular and humoral responses against a variety of pathogens causing infectious diseases and other non-infectious diseases. By displaying specific antigen epitopes or proteins on their coat proteins, IAVs have merited much study, as their unique abilities are exploited for widespread vaccine development. : The architectural traits of filamentous viruses and their derivatives, IAVs, facilitate the display of specific antigenic peptides which induce antibody production to prevent or curtail infection. Inoviruses provide a foundation for cost-efficient large-scale specific phage display. In this paper, the development of different applications of inovirus-based phage display vaccines across a broad range of pathogens and hosts is reviewed. The references cited in this review were selected from established databases based on the authors' knowledge of the study subject. : The importance of phage-display technology has been recently highlighted by the Nobel Prize in Chemistry 2018 awarded to George P. Smith and Sir Gregory P. Winter. Furthermore, the symbiotic nature of filamentous viruses infecting intestinal F strains offers an attractive platform for the development of novel vaccines that stimulate mucosal immunity.

Citing Articles

Genetically engineered bacteriophages as novel nanomaterials: applications beyond antimicrobial agents.

Kim S, Heo H, Kim C, Shin H Front Bioeng Biotechnol. 2024; 12:1319830.

PMID: 38725991 PMC: 11079243. DOI: 10.3389/fbioe.2024.1319830.


Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens.

Palma M Vaccines (Basel). 2023; 11(7).

PMID: 37514992 PMC: 10384025. DOI: 10.3390/vaccines11071176.


Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells.

Manco R, DApice L, Trovato M, Lione L, Salvatori E, Pinto E Viruses. 2023; 15(3).

PMID: 36992381 PMC: 10059692. DOI: 10.3390/v15030672.


PLGA microparticle formulations for tunable delivery of a nano-engineered filamentous bacteriophage-based vaccine: in vitro and in silico-supported approach.

Jamaledin R, Sartorius R, Di Natale C, Onesto V, Manco R, Mollo V J Nanostructure Chem. 2023; :1-16.

PMID: 36687278 PMC: 9838389. DOI: 10.1007/s40097-022-00519-9.


A New Vaccination Method Based on Phage NgoΦ6 and Its Phagemid Derivatives.

Piekarowicz A, Klyz A, Stein D Front Microbiol. 2022; 13:793205.

PMID: 35572628 PMC: 9096494. DOI: 10.3389/fmicb.2022.793205.


References
1.
Kwong P, Mascola J, Nabel G . Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013; 13(9):693-701. DOI: 10.1038/nri3516. View

2.
Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L . The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine. 2005; 23(40):4860-6. DOI: 10.1016/j.vaccine.2005.05.024. View

3.
Zhong Y, Cai J, Zhang C, Xing X, Qin E, He J . Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A. Virol J. 2011; 8:542. PMC: 3320565. DOI: 10.1186/1743-422X-8-542. View

4.
Frenkel D, Dewachter I, Van Leuven F, Solomon B . Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine. 2003; 21(11-12):1060-5. DOI: 10.1016/s0264-410x(02)00609-6. View

5.
Palacios-Rodriguez Y, Gazarian T, Rowley M, Majluf-Cruz A, Gazarian K . Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope. J Microbiol Methods. 2006; 68(2):225-35. DOI: 10.1016/j.mimet.2006.08.001. View